CymaBay Therapeutics Inventory Turnover Ratio 2013-2019 | CBAY

CymaBay Therapeutics inventory turnover ratio from 2013 to 2019. Inventory turnover ratio can be defined as a ratio showing how many times a company's inventory is sold and replaced over a period.
CymaBay Therapeutics Inventory Turnover Ratio Historical Data
Date
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.326B $0.010B
CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $56.958B 10.39
Mylan (MYL) United States $9.456B 4.17
Teva Pharmaceutical Industries (TEVA) Israel $8.189B 3.22
Bausch Health Cos (BHC) Canada $7.931B 5.29
Dr Reddy's Laboratories (RDY) India $6.415B 21.63
ASPEN PHARMACR (APNHY) South Africa $3.142B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.346B 13.16
Amphastar Pharmaceuticals (AMPH) United States $0.941B 46.35
Akorn (AKRX) United States $0.580B 0.00
Homology Medicines (FIXX) United States $0.572B 0.00
Voyager Therapeutics (VYGR) United States $0.544B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.420B 0.00
Assembly Biosciences (ASMB) United States $0.387B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.223B 0.30
Zynerba Pharmaceuticals (ZYNE) United States $0.187B 0.00
Sol-Gel Technologies (SLGL) Israel $0.151B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.111B 0.00
Teligent (TLGT) United States $0.043B 0.00